Innovent Biologics (IVBIY) announces the presentation of preclinical data for multiple novel cancer therapeutics at the 2025 AACR Annual Meeting in Chicago from April 25-30. The presentations include data on several groundbreaking molecules:
- IAR037: A novel CD40/PD-L1 bispecific antibody for advanced solid tumors
- IBI3010: A FRα targeting biparatopic antibody-drug conjugate
- IBI3019: A first-in-class EGFR/CDH17/CD16A tri-specific antibody for colorectal cancer
- IBI3026: A novel anti-PD-1/IL-12 fusion protein
- IBI3014: A TROP2xPD-L1 bi-specific ADC
The company will also present findings on combination therapies involving olverembatinib with lisaftoclax for leukemia treatment. These presentations showcase Innovent's expanding technological capabilities in developing first-in-class bispecific antibodies, multi-specific antibodies, and ADCs for oncology applications.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.